What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group.
OBJECTIVE
Short prostate specific antigen doubling time following recurrence after radical prostatectomy portends a poor prognosis in men with prostate cancer. We determined which demographic and clinicopathological variables were predictive of a short prostate specific antigen doubling time in a cohort of men with clinically localized prostate cancer treated with radical prostatectomy.


METHODS
Data on 856 men from the Shared Equal Access Regional Cancer Hospital database who underwent radical prostatectomy for node negative prostate cancer between 1988 and 2003 were included in the analysis. We used logistic regression analysis to determine the independent factors associated with a short prostate specific antigen doubling time of less than 9 months vs a longer doubling time of 9 months or greater, or no recurrence. The variables analyzed were patient age, race, logarithmically transformed preoperative prostate specific antigen, body mass index, year of surgery, pathological Gleason sum, extraprostatic extension, surgical margin status and seminal vesicle invasion.


RESULTS
On multivariate analysis higher preoperative prostate specific antigen (OR 2.20, 95% CI 1.52-3.19, p <0.001), pathological Gleason sum 8-10 (OR 4.70, 95% CI 2.11-10.43, p <0.001) and 7 (OR 2.11, 95% CI 1.09-4.08, p = 0.026), tumors with extraprostatic extension and/or positive surgical margins (OR 2.08, 95% CI 1.48-3.91, p = 0.023), and seminal vesicle invasion (OR 3.26, 95% CI 1.48-7.21, p = 0.003) were independent predictors of a short prostate specific antigen doubling time. Based on these risk factors we developed a table to estimate the risk of recurrence with a prostate specific antigen doubling time of less than 9 months.


CONCLUSIONS
The factors that are invariably used to predict overall biochemical recurrence following radical prostatectomy, including high prostate specific antigen, high grade and adverse pathological findings, also predict aggressive recurrence.
Teeter
Anna E
AE
Division of Urologic Surgery and Duke Prostate Center, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA.
Bañez
Lionel L
LL
Presti
Joseph C
JC
Aronson
William J
WJ
Terris
Martha K
MK
Kane
Christopher J
CJ
Amling
Christopher L
CL
Freedland
Stephen J
SJ
D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D001707:Biopsy, Needle; D016001:Confidence Intervals; D006801:Humans; D007150:Immunohistochemistry; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009364:Neoplasm Recurrence, Local / Q000097:blood* / Q000401:mortality / Q000473:pathology; D009367:Neoplasm Staging; D016017:Odds Ratio; D011182:Postoperative Care / Q000379:methods; D011237:Predictive Value of Tests; D011300:Preoperative Care / Q000379:methods; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood*; D011468:Prostatectomy / Q000009:adverse effects / Q000379:methods*; D011471:Prostatic Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D012042:Registries; D012307:Risk Factors; D012680:Sensitivity and Specificity; D016019:Survival Analysis; D013997:Time Factors
D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen
J Urol. 2001 Jan;165(1):119-25
11125379
J Urol. 2002 Jan;167(1):103-11
11743285
Urology. 2002 Oct;60(4):670-4
12385931
J Urol. 2003 Jun;169(6):2142-6
12771736
J Natl Cancer Inst. 2003 Sep 17;95(18):1376-83
13130113
Cancer Chemother Rep. 1966 Mar;50(3):125-8
5948714
JAMA. 1998 Sep 16;280(11):969-74
9749478
JAMA. 1999 May 5;281(17):1591-7
10235151
J Clin Oncol. 1999 May;17(5):1499-507
10334537
Urology. 2005 Mar;65(3):528-32
15780370
JAMA. 2005 Jul 27;294(4):433-9
16046649
J Clin Oncol. 2005 Aug 1;23(22):4975-9
16051949
Eur Urol. 2005 Oct;48(4):541-5
16139417
Urol Int. 2006;77(2):130-4
16888417
J Urol. 2006 Oct;176(4 Pt 1):1404-8
16952644
JAMA. 2006 Nov 15;296(19):2329-35
17105795
Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):1064-71
16979837
Urol Oncol. 2007 Mar-Apr;25(2):110-4
17349524
J Clin Oncol. 2007 May 1;25(13):1765-71
17470867
Urology. 2007 Jun;69(6):1095-101
17572194